BioRestorative Therapies (BRTX) Interest Expenses (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Interest Expenses came in at $22.6 million in Q4 2025, up 52099.24% YoY from N/an in Q4 2024, and up 6006.36% on a QoQ basis from $369844.0 in Q2 2025.
BioRestorative Therapies (BRTX) Interest Expenses (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Interest Expenses data on file, last reported at $22.6 million in Q4 2025.
- Quarterly Interest Expenses rose 52099.24% year-over-year to $22.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 13337.9% YoY) and the FY2025 annual result came in at $22.6 million, down 23.27% from the prior year.
- Interest Expenses advanced to $22.6 million in Q4 2025, from $369844.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $22.6 million in Q4 2025 to a low of $851.0 in Q3 2024.
- A 5-year average of $1.3 million and a median of $42007.0 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 94.79% — and 2025, when it soared 52099.24%.
- Tracing BRTX's Interest Expenses over 5 years: stood at $39593.0 in 2021, then increased by 3.01% to $40783.0 in 2022, then climbed by 3.0% to $42007.0 in 2023, then climbed by 2.99% to $43265.0 in 2024, then soared by 52099.24% to $22.6 million in 2025.
- The last three Interest Expenses figures came in at $22.6 million (Q4 2025), $369844.0 (Q2 2025), and $566088.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.58 Mn |
| Dec 31, 2025 | 22.58 Mn |
| Jun 30, 2025 | 369,844.00 |
| Jun 30, 2025 | 369,844.00 |
| Mar 31, 2025 | 566,088.00 |
| Mar 31, 2025 | 566,088.00 |
| Dec 31, 2024 | 43,265.00 |
| Dec 31, 2024 | 43,265.00 |
| Sep 30, 2024 | 851.00 |
| Sep 30, 2024 | 851.00 |
| Jun 30, 2024 | 2,950.00 |
| Jun 30, 2024 | 2,950.00 |
| Mar 31, 2024 | 129,795.00 |
| Mar 31, 2024 | 129,795.00 |
| Dec 31, 2023 | 42,007.00 |
| Dec 31, 2023 | 42,007.00 |
| Sep 30, 2023 | 16,343.00 |
| Sep 30, 2023 | 16,343.00 |
| Jun 30, 2023 | 23,014.00 |
| Jun 30, 2023 | 23,014.00 |